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Abstract
BACKGROUND AND PURPOSE: The purpose of this study was to derive quantitative parameters from magnetic
resonance (MR) spectroscopic, perfusion, and diffusion imaging of grade 2 gliomas according to the World Health
Organization and to investigate how these multiple imaging modalities can contribute to evaluating their histologic
subtypes and spatial characteristics. MATERIALS AND METHODS: MR spectroscopic, perfusion, and diffusion
images from 56 patients with newly diagnosed grade 2 glioma (24 oligodendrogliomas, 18 astrocytomas, and
14 oligoastrocytomas) were retrospectively studied. Metabolite intensities, relative cerebral blood volume (rCBV),
and apparent diffusion coefficient (ADC) were statistically evaluated. RESULTS: The 75th percentile rCBV and me-
dian ADC were significantly different between oligodendrogliomas and astrocytomas (P< .0001) and between oligo-
dendrogliomas and oligoastrocytomas (P < .001). Logistic regression analysis identified both 75th percentile rCBV
and median ADC as significant variables in the differentiation of oligodendrogliomas from astrocytomas and oligo-
astrocytomas. Group differences in metabolite intensities were not significant, but there was a much larger variation
in the volumes and maximum values of metabolic abnormalities for patients with oligodendroglioma compared with
the other tumor subtypes. CONCLUSIONS: Perfusion and diffusion imaging provide quantitative MR parameters that
can help to differentiate grade 2 oligodendrogliomas from grade 2 astrocytomas and oligoastrocytomas. The large
variations in the magnitude and spatial extent of the metabolic lesions between patients and the fact that their
values are not correlated with the other imaging parameters indicate that MR spectroscopic imaging may provide
complementary information that is helpful in targeting therapy, evaluating residual disease, and assessing response
to therapy.
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Introduction
Grade 2 gliomas are low-grade brain tumors that are diffusely infil-
trating, slow-growing, and seen primarily in younger patients [1].
They comprise three major subtypes of tumors: oligodendrogliomas,
oligoastrocytomas, and astrocytomas. Accurate characterization of
these subtypes has its clinical importance in that they have different
prognosis and response to therapy. Clinical observations have shown
that oligodendrogliomas are more likely to respond to chemotherapy
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and patients with these tumors have better treatment outcome and
longer survival times than patients with astrocytomas and oligoastro-
cytomas [2–4]. The diagnosis and classification of grade 2 gliomas cur-
rently rely on the histopathologic examination of biopsy specimens,
but variations in tissue sampling for these heterogeneous tumors and
restrictions on surgical accessibility make it difficult to be sure that
the samples obtained are representative of the entire tumor [5].
Anatomic magnetic resonance (MR) imaging of the brain provides
excellent soft tissue contrast and is routinely used for the noninvasive
assessment of brain tumors, but its ability to define tumor type and
grade of gliomas is limited [6]. New MR imaging modalities such as
proton MR spectroscopic imaging (MRSI), perfusion-weighted im-
aging (PWI), and diffusion-weighted imaging (DWI) have been pro-
posed as alternate methods for characterizing such tumors [7]. MRSI
provides an assessment of the metabolic signature of brain tumors
[8–10]. PWI measures relative cerebral blood volume (rCBV), which
reflects variations in microvessel density [11–13]. Apparent diffusion
coefficient (ADC) is derived from DWI and reflects changes in tissue
structure [14–16].
Preliminary studies have demonstrated differences in metabolic
parameters between high- and low-grade gliomas [17] but did not
attempt to evaluate differences between subtypes of grade 2 gliomas.
Although most grade 2 lesions have limited gadolinium enhance-
ment, grade 2 oligodendrogliomas have been reported to have sig-
nificantly higher maximum rCBV than grade 2 astrocytomas [18].
Evaluation of whole tumor ADC histograms [19] or ADC from tu-
mor lesions [20] indicated that there are also differences in ADC be-
tween grade 2 oligodendrogliomas and astrocytomas. However, there
have been few efforts so far to combine information from MRSI,
PWI, and DWI to characterize subtypes of grade 2 gliomas. In the
current study, we have expanded on previous work by investigating
the characteristics of grade 2 gliomas in a larger population of pa-
tients using multiparametric MR imaging. The purpose was to deter-
mine whether the combination of metabolic, perfusion, and diffusion
data could be helpful in targeting routine tissue sampling and hence
augment the assessment of histologic subtypes for grade 2 gliomas.
Materials and Methods
Patients
Fifty-six patients with newly diagnosed grade 2 glioma according to
the World Health Organization who had been scanned 1 day before
surgery were selected for this study, including 24 with oligodendro-
gliomas (10 females and 14 males; median age, 43 years; range, 21-
71 years), 18 with astrocytomas (7 females and 11 males; median
age, 33.5 years; range, 22-52 years), and 14 with oligoastrocytomas
(5 females and 9 males; median age, 45 years; range, 18-62 years).
The ADC values for a subset of this patient population had been
reported in a previous study [20], but the correlation of these data
with other imaging parameters had not been considered. Informed
consent to participate in the study was obtained using a protocol that
had been reviewed and approved by the committee on human research
at our institution. The clinical diagnosis was made by an experienced
neuropathologist. For consensus diagnosis, a second neuropathologist
independently reviewed all cases, and special stains were performed
as necessary. Tumors that were classified as oligodendroglioma dem-
onstrated the hallmark histopathologic features as defined by theWorld
Health Organization’s criteria [1].
MR Protocol
MR imaging was performed on a 1.5-T GE scanner (GE Medical
Systems, Milwaukee, WI) equipped with a standard quadrature head
coil. Anatomic T2-weighted three-dimensional fast spin-echo (FSE)
image (time to repetition [TR]/time to echo [TE] = 4000/104 milli-
seconds, field of view [FOV] = 260 × 195 mm2) and T1-weighted
pre- and post-gadolinium three-dimensional spoiled gradient-echo
images (TR/TE = 34/3 milliseconds, flip angle = 40°, FOV = 260 ×
195 mm2) were obtained from all patients. MRSI data were obtained
from 47 of 56 patients using a three-dimensional chemical shift imag-
ing multivoxel sequence and point-resolved spectral selection volume
selection to cover as much of the lesion and surrounding normal tis-
sue as possible. Imaging parameters were as follows: TR/TE = 1000/
144 milliseconds, voxel size = 1 ml, phase-encoding arrays = 12 × 12 ×
8 or 16 × 16 × 8. The acquisition of DWI in all 56 patients included
either three gradient directions or six gradient directions (TR/TE =
1000/110 milliseconds, matrix size = 256 × 256, low/high b value =
5/1000 sec/mm2, slice number/thickness = 28/3-5 mm). The PWI
was obtained from 54 of 56 patients during injection of a bolus of
0.1-mmol/kg body weight of gadopentetate dimeglumine (Gd-DTPA)
contrast agent at a rate of 5 ml/sec. A series of 60 T2*-weighted
gradient-echo, echo-planar images were acquired during the first pass
of the contrast agent bolus injection (TR/TE = 1000-1250/54 millisec-
onds, flip angle = 35°, matrix size = 128 × 128, slice number/thickness =
8/3-6 mm).
Data Processing
T2-weighted FSE and T1-weighted postcontrast images were first
reformatted to create corresponding volume images. The T2-weighted
FSE images were aligned to the T1-weighed postcontrast images using
a rigid body surface matching method [21], whereas the PWI and
DWI images were aligned using a rigid body mutual information algo-
rithm [22]. Three-dimensional regions of interest (ROIs) correspond-
ing to the hyperintensity region on T2-weighted FSE images (T2ALL)
were delineated using an in-house semiautomatic program. The T1-
weighted postcontrast images were examined to see if there were
contrast-enhancing lesions in the T2ALL, which occurred in 6 of
56 patients, and the nonenhancing region was contoured as NEL =
T2ALL − CEL. The ROIs of NEL were saved and transferred to
metabolite, rCBV, and ADC maps for subsequent intensity analysis.
ROIs were also drawn within normal-appearing white matter (NAWM)
for use in normalizing rCBV maps.
The spectroscopy datawere reconstructed to create a three-dimensional
array of spectra from voxels on a regularly spaced grid using themethod
proposed previously [23]. Voxels that contain more than 50% of
NEL and 75% NAWM were identified as tumor and normal voxels,
respectively. Median intensities of choline (Cho), creatine (Cre), and
N -acetyl aspartate (NAA) were determined from tumor voxels and
were normalized by median values of normal voxels in the same pa-
tient. The Cho-to-NAA index (CNI) was estimated based on the
differences in relative peak heights between tumor and normal tissues
[24]. Briefly, an iterative algorithm is used to select a population of
voxels that have the spectral features of normal brain regions; then
the selected voxels are used as internal controls to quantify the proba-
bility of abnormality at each voxel location. Measures of the spatial
extent of the metabolic lesions were obtained by considering the num-
ber of voxels that had CNI values greater than 2 or 3.
Perfusion images were resampled to a 32 × 32 in-plane grid so that
the observed signal changes had sufficient signal-to-noise ratio to be
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analyzed reliably on a voxel-by-voxel basis. The change of T2* signal
intensity over time were processed to produce a map of rCBV [25].
Diffusion images were processed to generate ADC maps using an in-
house program based on the mutilinear regression method from
Basser et al. [26]. The mean, median, 25th percentile, and 75th percen-
tile signal intensities of ADC and rCBV within NEL were recorded
for each patient. Normalized rCBV values were obtained by dividing
the calculated values from NEL by median values from NAWM.
Statistical Analysis
The nonparametric Wilcoxon rank sum test was used to evaluate
differences among groups. Multiple comparisons between groups
were corrected by using the Bonferroni method. Univariate logistic
regression analysis was applied to quantify the contribution of each
individual variable to discriminate the tumor subtypes. Multivariate
logistic regression analysis was performed to determine whether the
combinations of these variables could further improve the discrimi-
nation. The cutoff probability for the classification of subtypes in lo-
gistic regression analyses was set at 0.5. To evaluate the accuracy of
the models for prediction, the probability of a lesion being in one
versus the other subtype was estimated from the model and the lesion
was assigned to the group for which the probability was higher. This
probability estimate is conditional on the proportion of cases of each
type in the sample. When the correlation between two variables was
calculated, it referred to partial correlation adjusted by tumor sub-
type. The level of significance of difference was defined by a P value
<.05. In the case of performing the Bonferroni correction, statistical
significance was defined as P < .05/k, where k is the number of total
comparisons. Statistical analysis was performed using SPSS (SPSS,
Chicago, IL).
Results
All 56 patients had regions of hyperintensity on the T2-weighted images
and 6 of them had regions of contrast enhancement on T1-weighted
postcontrast images. The median tumor volume was 40 ml for pa-
tients with oligodendroglioma (range, 4-257 ml; contrast-enhancing
n = 3), 39 ml for patients with astrocytoma (range, 10-160 ml; contrast-
enhancing n = 1), and 55ml for patients with oligoastrocytoma (range,
1-114 ml; contrast-enhancing n = 2). As can be seen, although the
median lesion volumes were similar among subtypes, the large ranges
indicated that the volumes were highly variable within each subgroup.
Figures 1, 2, and 3 show representative examples of the data from
patients with grade 2 oligodendroglioma, astrocytoma, and oligo-
astrocytoma, respectively. Note that the ADC is elevated in the tu-
mor relative to NAWM for all three patients, but the lesion from the
patient with astrocytoma appears to have higher ADC than the le-
sions from the patients with oligodendroglioma and oligoastrocytoma.
The patient with oligodendroglioma has a region on its rCBV map
within the lesion that has higher rCBV values than NAWM. All three
patients had voxels with reduced NAA and substantially elevated Cho
relative to normal.
Evaluation of rCBV and ADC Values for Tumor Subtypes
All measurements of rCBV and ADC showed similar statistical
significance in group comparisons. The median ADC and 75th per-
centile rCBV were chosen to be representative of results. The 75th
percentile rCBV was chosen because it represents the most abnormal
portion of the tumor and also avoids having the significance of the
data being driven by only a few voxels as would be the case if the max
rCBV were used [18]. Table 1 shows the average of the 75th percen-
tile rCBV and the median ADC for each subtype. Higher 75th per-
centile rCBV (2.16 ± 0.50) and lower median ADC (1.21 ± 0.15 ×
10−3 mm2/sec) were observed in oligodendrogliomas compared with
astrocytomas (75th percentile rCBV 1.38 ± 0.41; median ADC
1.52 ± 0.20 × 10−3 mm2/sec). Oligoastrocytomas had 75th percentile
rCBV (1.49 ± 0.44) and median ADC (1.41 ± 0.15 × 10−3 mm2/sec)
values intermediate to those from oligodendrogliomas and astro-
cytomas. None of the PWI and DWI parameters were found to be
significantly different between astrocytomas and oligoastrocytomas
and so no further statistical analysis was performed between them.
Differences in rCBV and ADC for Oligodendrogliomas
versus Astrocytomas
The differences in 75th percentile rCBV and median ADC be-
tween oligodendrogliomas and astrocytomas were significant (P <
.0001 and P < .00001, respectively). The P values listed in Tables 1
and 4 are nominal P values unadjusted for multiple comparisons.
Using the Bonferroni adjustment, comparisons would only be con-
sidered statistically significant if the nominal P value was less than
.0018 ≈ .05/27, where 27 was the total number of comparisons in
Tables 1 and 4. Logistic regression analysis was performed for the
patients who underwent both perfusion and diffusion studies. This
included 22 patients with oligodendroglioma and 18 patients with
astrocytoma. Table 2 gives the results from both univariate and bi-
variate logistic regression analyses. In univariate analysis, 77.5% (31/
40) and 85% (34/40) of the patients were correctly classified using
75th percentile rCBV and median ADC, respectively. Of those being
correctly classified patients by either 75th percentile rCBVor median
ADC, 26 of them were correctly classified by both variables. When
75th percentile rCBVand median ADC were combined in a bivariate
analysis, they were both significant variables (P = .034 for 75th per-
centile rCBV; P = .012 for median ADC), and 92.5% (37/40) of the
patients were correctly classified.
Differences in rCBV and ADC for Oligodendrogliomas
versus Oligoastrocytomas
A similar comparison between oligodendrogliomas and oligoastro-
cytomas showed that the differences in 75th percentile rCBV and
median ADC between oligodendrogliomas and oligoastrocytomas
were significant (P < .001 in both cases). The results from the anal-
ysis with logistic regression are shown in Table 3. The regression cor-
rectly classified 75% (27/36) of original grouped patients with the
use of 75th percentile rCBV or median ADC alone. Of those being
correctly classified patients by either the 75th percentile rCBV or the
median ADC, 22 of them were correctly classified by both variables.
Again the 75th percentile rCBV (P = .031) and median ADC (P =
.049) were significant variables in bivariate analysis, and 83.3% (30/
36) of the patients were correctly classified.
Metabolite Levels and Lesion Volumes
Table 4 gives metabolite levels and indices within the portion of
NEL that was covered by the point-resolved spectral selection box.
Oligodendrogliomas had higher median Cho (1.48 ± 0.57), Cre
(0.95 ± 0.21), and NAA (0.48 ± 0.15) than astrocytomas (median
Cho 1.19 ± 0.26; median Cre 0.83 ± 0.20; median NAA 0.40 ±
0.14) and oligoastrocytomas (median Cho 1.14 ± 0.19; median Cre
0.86 ± 0.11; median NAA 0.42 ± 0.12). These differences were not
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significant due to the substantial variability in metabolite levels among
patients within each subtype. The median numbers of voxels with
CNI > 2 or CNI > 3, the median CNI for CNI > 2, and the median
of the maximum CNI values did not change substantially between sub-
types, but again there were large variations between different patients.
Examples of differences in the metabolic lesions for two patients with
oligodendroglioma are seen in Figure 4.
Correlations between Parameters
The 75th percentile rCBV and median ADC were inversely corre-
lated with R = −0.52 (P < .001). The ADC values in the voxels with
maximum CNI were correlated with the median ADC from NEL
with R = 0.70 (P < .001). There was no correlation between the max-
imum CNI and ADC at the corresponding location or between the
median CNI and median ADC from NEL.
Discussion
Accurate classification of grade 2 infiltrating gliomas and evaluation
of tumor burden have important implications for diagnosis, prog-
nosis, and selection of the most appropriate therapy. As was seen
from the evaluation of anatomic images, most of these lesions are
nonenhancing on T1-weighted postcontrast images and the lesions
observed on T2-weighted images can be large, with relatively uni-
form intensity. This means that selecting the most appropriate region
Figure 1. MR images and spectra from a patient with oligodendroglioma. (A) Axial T2-weighted FSE image with contours of T2ALL
(black) and NAWM (white). (B) T1-weighted postcontrast image showing no contrast enhancement. (C) rCBV map showing a large focus
of increased blood volume (arrows) in the tumor. (D) ADCmap showingmildly increasedmagnitude of diffusion (arrows) in the tumor. (E and
F) T2-weighted FSE image overlaid with arrays of spectra showing voxels with elevated Cho and reduced NAA peaks in the tumor.
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for tissue sampling to make an accurate diagnosis is problematic and
would therefore benefit from having imaging information that distin-
guishes regions of the tumor with different physiological or metabolic
characteristics. In the present study, we were interested in determining
whether data from MRSI, PWI, and DWI could provide parameters
that could be used for targeting tissue sampling and for providing in-
formation that would contribute to the characterization and thera-
peutic planning for patients with grade 2 glioma.
MRSI is a method that measures chemical markers of neoplastic
activity. Spectra from brain tumors have increased Cho, which corre-
lates with membrane biosynthesis by proliferating cells, and reduced
NAA, which indicates loss of neuronal integrity due to tumor cell
infiltration [8]. In this study, reduced NAA and increased Cho were
found in all grade 2 glioma subtypes with a trend toward higher Cho
in oligodendroglioma than in astrocytoma and oligoastrocytoma.
This trend may be explained by the fact that oligodendrogliomas
have been reported to be more proliferative than astrocytomas
[27,28]. The varying levels of NAA that were observed in these le-
sions may be due to the limited spatial resolution of the MRSI data,
which allows voxels on the edge of the tumor to include some normal
brain tissue or to the heterogeneity within the tumor itself, which
may include a mixture of infiltrative tumor and residual normal tissue.
No significant differences in individual metabolite values were found
between subtypes, which is consistent with previous studies [29–31].
Figure 2. MR images and spectra from a patient with astrocytoma. (A) Axial T2-weighted FSE image. (B) T1-weighted postcontrast
image showing no contrast enhancement. (C) rCBV map showing minimally increased blood volume (arrows) in the tumor. (D) ADC
map showing a large focus of increased magnitude of diffusion (arrows) in the tumor. (E and F) T2-weighted FSE image overlaid with
arrays of spectra showing voxels with elevated Cho and reduced NAA peaks in the tumor.
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The CNI is a quantitative parameter that describes the differences
in Cho and NAA relative to normal tissue and that has been shown
to be sensitive to the presence of tumor [32]. From our studies, it
seems that obtaining a tissue sample from the region with highest
CNI is likely to reveal the area with the highest density of tumor cells
and lowest amount of normal brain. Thus, whereas there is an over-
lap between the CNI levels for different histologic subtypes, the
highest CNI levels are observed in oligodendrogliomas and these
in vivo measurements may be useful in directing a surgeon to the
location that gives the most definitive histologic diagnosis. Previous
studies that examined the correlation between metabolite levels and
tissue biopsies have suggested that the ratio of Cho to NAA and the
level of Cho relative to Cre in normal brain may be more effective in
defining the borders of the tumor than the region of hyperintensity
on T2-weighted images [33]. These values may also be important in
postsurgical MR examinations for evaluating residual tumor or for
assessing response to therapy. Although the echo time used in this
study precluded the quantification of levels of glutamate, previous
reports indicated that these may also be relevant in distinguishing
grade 2 oligodendrogliomas from astrocytomas [30].
PWI provides measurements of rCBV that reflect tumor angio-
genesis and vascularity. In our study, the 75th percentile rCBV of
Figure 3.MR images and spectra from a patient with oligoastrocytoma. (A) Axial T2-weighted FSE image. (B) T1-weighted postcontrast
image showing no contrast enhancement. (C) rCBV map showing mildly increased blood volume (arrows) in the tumor. (D) ADC map
showing mildly increased magnitude of diffusion (arrows) in the tumor. (E and F) T2-weighted FSE image overlaid with arrays of spectra
showing voxels with elevated Cho and reduced NAA peaks in the tumor.
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oligodendrogliomas was significantly higher than the value for astro-
cytomas or oligoastrocytomas. This difference may be explained by
the fact that oligodendrogliomas are more likely to exhibit micro-
vascular proliferation than the astrocytomas and oligoastrocytomas
[34,35]. Statistical analysis showed that the 75th percentile rCBV
was a significant variable in the differentiation of oligodendrogliomas
from each of the other two subtypes. These results confirm observa-
tions from a previous study in a smaller population of patients, which
found that the maximum rCBV within the tumor was significantly
higher for oligodendrogliomas than for astrocytomas [18].
ADC values derived from diffusion MR imaging provide a mea-
surement of the movement of water molecules within tissue micro-
structures. Although ADC is thought to correlate to cell density in
high-grade tumors [16], both the results of this study and the obser-
vations made in previous studies have indicated that there is no clear
correlation between ADC and levels of Cho for grade 2 gliomas
[17,36]. One explanation of this is that the levels of ADC observed
in these lesions are also influenced by other biologic factors, such as
the presence of edema and calcification. Edema represents an increase
of free extracellular water content of tissue and should therefore re-
sult in a higher ADC [37,38]. It is reasonable to expect that there
would be more edema in astrocytomas than oligodendrogliomas be-
cause they are more infiltrative. Calcification is more common in
oligodendrogliomas [39] and results in a relatively lower ADC be-
cause it limits water content and restricts water movement. The
values for oligodendrogliomas that were observed in this study are
in agreement with previous data, which use the analysis of whole-
tumor ADC histograms [19].
The classification accuracy of the logistic regression model based
on median ADC was higher than that based on the 75th percentile
rCBV. When they were both included in the regression, the accuracy
showed a slight improvement over median ADC alone, with 3 of
40 additional patients for the analysis of oligodendrogliomas versus
astrocytomas and 3 of 36 additional patients for the analysis of oligo-
dendrogliomas versus oligoastrocytomas being correctly classified.
The similarity in classification between the two variables was most
likely due to the 75th percentile rCBV and the median ADC being
inversely correlated, which indicates that increased vascularity and re-
stricted diffusion were present in a coordinated fashion. It should be
noted that there are limitations on these assessments based on the
logistic models. First, the classification accuracy of the model is being
evaluated using the same data set used to create the model. This will
tend to overestimate the ability of the model to predict for an inde-
pendent set of cases. In addition, by setting the cutoff probability to
be 0.5, we assume that the proportion of cases with the specified sub-
types would accurately represent the proportions seen in the general
population of cases. Even with these caveats, the results provide
strong evidence that both the 75th percentile rCBV and the median
ADC provide useful information for distinguishing oligodendro-
gliomas from astrocytomas and oligoastrocytomas.
Oligoastrocytomas contain variable proportions of cell populations
that display both astrocytic and oligodendroglial phenotypes [1]. The
MR findings obtained in our study reflected the mixed cellular
phenotypes of these tumors in that they had 75th percentile rCBV
and median ADC values that fell in between those of oligodendro-
gliomas and astrocytomas. It should be noted that although our re-
sults are consistent with several other studies that have reported on
differences in imaging characteristics for grade 2 gliomas, the histo-
logic criteria for distinguishing oligoastrocytomas from oligodendro-
gliomas and astrocytomas may vary between institutions. Low-grade
gliomas display a broad range of cellular phenotypes, with the classic
oligodendrogliomas and astrocytomas being at different ends of a dis-
continuous spectrum [40]. It is therefore possible that some of the
patients whom we defined as having oligoastrocytoma would have
been diagnosed as having oligodendroglioma or astrocytoma in other
institutions. For the purposes of our study, we focused on identifying
only those tumors with hallmark histopathologic features as oligo-
dendrogliomas, whereas the criteria used to separate oligoastrocytomas
and astrocytomas were less distinctive. It is therefore not surprising
that these two subpopulations had similar features and could not be
distinguished based on the MR parameters considered.
One of the limitations of the current study is that we were unable
to make a direct link between the MR imaging parameters and the
histologic examinations because the sample used for diagnosis was
not targeted based on metabolic and physiological imaging data.
Thus, although the MR findings from this study were attributed
Table 1. Average of Median ADC and the 75th Percentile rCBV in NEL for Each Grade 2 Glioma Subtype (Data Are Presented as Mean ± SD) and P Values from a Wilcoxon Rank Sum Test.
Parameter OD OA AC P: OD vs AC P: OD vs OA P : AC vs OA
Median ADC*,† 1.21 ± 0.15 1.41 ± 0.15 1.52 ± 0.20 <.00001 <.001 .106
75th percentile rCBV‡ 2.16 ± 0.50 1.49 ± 0.44 1.38 ± 0.41 <.0001 <.001 .582
P values in bold face font indicate statistical significance.
AC indicates astrocytoma; OA, oligoastrocytoma; OD, oligodendroglioma (similar to Tables 2–4).
*MR diffusion cases: OD (n = 24), OA (n = 14), and AC (n = 18).
†Units of ADC are 10−3 mm2/sec.
‡MR perfusion cases: OD (n = 22), OA (n = 14), and AC (n = 18).
Table 2. Number of Correct Assignments Using the 75th Percentile rCBV, Median ADC, and
Their Combination in the Differentiation of Oligodendrogliomas from Astrocytomas.
OD and AC (%) OD (%) AC (%)
75th percentile rCBV* 31/40 (77.5) 18/22 (81.8) 13/18 (72.2)
Median ADC* 34/40 (85.0) 19/22 (86.4) 15/18 (83.3)
75th percentile rCBV + median ADC† 37/40 (92.5) 20/22 (90.9) 17/18 (94.4)
*Univariate analysis.
†Bivariate analysis.
Table 3. Number of Correct Assignments Using the 75th Percentile rCBV, Median ADC, and
Their Combination in the Differentiation of Oligodendrogliomas from Oligoastrocytomas.
OD and OA (%) OD (%) OA (%)
75th percentile rCBV* 27/36 (75.0) 18/22 (81.8) 9/14 (64.3)
Median ADC* 27/36 (75.0) 19/22 (86.4) 8/14 (57.1)
75th percentile rCBV + median ADC† 30/36 (83.3) 20/22 (90.9) 10/14 (71.4)
*Univariate analysis.
†Bivariate analysis.
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to histopathologic factors such as neoangiogenesis, cell density, pres-
ence of edema, and calcification, we cannot be certain as to the con-
tribution that each individual factor makes to each measurement.
Further studies that directly correlate imaging with histologic ob-
servations will be important for enhancing the interpretation of MR-
derived parameters. We recommend targeting locations within the
region of T2 hyperintensity with the highest CNI value, elevated
rCBV, or ADC values in the ranges that were found to be indicative
of oligodendrogliomas or astrocytomas. Note that there was a direct
correlation between ADC values at the location with maximum
CNI with the median ADC values. This indicates that targeting the
region with the most abnormal metabolism should provide represen-
tative data for the entire tumor.
Another factor that may be important for future studies is to use
recent advances in genetics to develop more accurate and prognosti-
cally relevant tumor classification systems. Reports based on molec-
ular biology of gliomas have suggested that loss of heterozygosity
chromosomes 1p and 19q is typical of oligodendrogliomas, whereas
mutation of TP53 gene is far more likely to associate with astro-
cytomas [5,41,42]. These findings have increased the interest in
Table 4. Summary of Parameters from MRSI in NEL for Each Grade 2 Glioma Subtype and P Values from a Wilcoxon Rank Sum Test.
Parameter OD, n = 20 OA, n = 12 AC, n = 15 P: OD vs AC P: OD vs OA P: AC vs OA
Median Cho* 1.48 ± 0.57 1.14 ± 0.19 1.19 ± 0.26 .178 .155 .757
Median Cre 0.95 ± 0.21 0.86 ± 0.11 0.83 ± 0.20 .093 .124 .757
Median NAA 0.48 ± 0.15 0.42 ± 0.12 0.40 ± 0.14 .066 .227 .857
No. of voxels with CNI > 2† 24 27.5 20 .652 .922 .751
5-160 10-46 4-53
No. of voxels with CNI > 3 8.5 12 9 .987 .984 .807
0-129 0-25 1-37
Median CNI for CNI > 2 voxels 3.02 2.89 3.03 .665 .586 .643
2.23-6.1 2.18-3.94 2.17-3.69
Max CNI 5.91 5.48 5.11 .217 .425 .510
2.47-16.78 2.87-7.66 3.04-8.22
*Numbers are median ± SD.
†Numbers are median and range.
Figure 4. T2-weighted FSE images (left) and spectra (right) from two patients who had oligodendrogliomas but with a different number
of voxels with elevated CNI. Voxels highlighted in light gray have CNI > 2 and voxels highlighted in dark gray have CNI > 3. Patient A had
160 voxels with CNI > 2, 129 voxels with CNI > 3, and the max CNI = 16.8. Patient B had 10 voxels with CNI > 2, no voxels with CNI >
3, and the max CNI = 2.9.
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investigating the relationship among MR imaging findings, glioma
genotype, and histologic type [31,43–45]. By performing these
correlation studies, it will be possible to develop more definitive
reference standards for glioma subtypes and to validate the use of
MR imaging parameters as noninvasive biomarkers for directing
surgical sampling, evaluating tumor burden, and assessing response
to therapy.
Conclusions
The results of this study showed that PWI and DWI were useful in
differentiating grade 2 oligodendroglioma from grade 2 astrocytomas
and oligoastrocytomas. The variations in maximum CNI and the
number of voxels with abnormal CNI indicate that there is a much
larger range of values in the oligodendrogliomas than for the other
histologic subtypes. Using these imaging methods to target tissue
sampling may be valuable in overcoming some of the limitations as-
sociated with histopathologic examinations and may contribute to
designing the treatment plan that best matches the characteristics
of the tumor. These observations may also be valuable for targeting
therapy, evaluating residual disease, and assessing response to therapy.
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